Ferinject approved in China for the treatment of iron deficiency in adult patients

28 November 2022 - China has the world’s largest iron deficiency anaemia population with estimated prevalence of 15%. ...

Read more →

Lantheus announces the approval of Definity (perflutren lipid microsphere) by China’s NMPA

28 November 2022 - Definity is the leading diagnostic ultrasound enhancing agent for patients with suboptimal echocardiograms. ...

Read more →

Junshi Biosciences announces approval of supplemental application for additional indications of adalimumab injection

22 November 2022 - Shanghai Junshi Biosciences announced today that the supplemental application for additional indications of adalimumab injection (UBP1211) for ...

Read more →

Calliditas' partner Everest Medicine's new drug application for Nefecon is accepted by the China NMPA

15 November 2022 - Calliditas Therapeutics today announced that the Chinese regulatory authority NMPA has accepted Everest Medicines' new drug application ...

Read more →

Henlius' novel anti-PD-1 mAb Hansizhuang (serplulimab) receives NMPA approval for the treatment of sqNSCLC

1 November 2022 - Shanghai Henlius Biotech announced that its first self-developed innovative anti-PD-1 monoclonal antibody Hansizhuang (serplulimab), in combination with ...

Read more →

Akeso's ivonescimab granted breakthrough therapy designation by China NMPA for the treatment of advanced NSCLC

20 October 2022 - Akeso announced that the Center for Drug Evaluation of China NMPA has granted breakthrough therapy designation ...

Read more →

CARsgen announces NDA acceptance of BCMA CAR T zevor-cel (CT053) by China NMPA

18 October 2022 - CARsgen Therapeutics announces that the NMPA of China has accepted the new drug application for zevorcabtagene autoleucel ...

Read more →

The China NMPA approved Cyramza (ramucirumab) for the treatment in patients with hepatocellular carcinoma

9 October 2022 - Innovent Biologics is pleased to see that the NMPA of China has approved the supplemental new drug ...

Read more →

JW Therapeutics announces NMPA approval of relmacabtagene autoleucel injection in patients with relapsed or refractory follicular lymphoma

11 October 2022 - JW Therapeutics announced that the NMPA of China has approved the supplemental new drug application for its ...

Read more →

China NMPA approves selpercatinib for the treatment of patients with RET driven lung and thyroid cancers

9 October 2022 - Innovent Biologics is pleased to see that the NMPA of China has approved the new drug application ...

Read more →

Toray receives approval from China’s NMPA for Careload to treat pulmonary arterial hypertension

28 September 2022 - Toray Industries announced today that it has received approval from China’s NMPA for Careload tablets to treat ...

Read more →

Lynparza approved in China as first-line maintenance treatment with bevacizumab for HRD positive advanced ovarian cancer

22 September 2022 - One in two women with advanced ovarian cancer has an HRD positive tumour. ...

Read more →

Junshi Biosciences receives NMPA approval of sNDA for toripalimab in combination with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer

20 September 2022 - Sixth approved indication of toripalimab in China, bringing more treatment options to patients with advanced non-small-cell ...

Read more →

CStone announces China’s NMPA has accepted and granted priority review to the supplemental new drug application for sugemalimab in the treatment of patients with relapsed or refractory extranodal natural killer/T-cell lymphoma

13 September 2022 - GEMSTONE-201 is the largest registrational clinical study of an anti-PD-(L)1 antibody reported so far in patients with ...

Read more →

ViewRay announces China NMPA approval of its MRIdian MRI guided radiation therapy for cancer patients

7 September 2022 - This approval expands MRIdian's global reach and offers cancer patients a new radiation therapy option—MRIdian SMART. ...

Read more →